speb/financial-data huggingface dataset:
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 912996000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 500397000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 19744000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 274983000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 312271000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 731544000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 14581818.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 0.33
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 368545000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 26854000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 26854000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 14581818.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 0.33
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 4812000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — EBIT: 55792000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — EBITDA: 82646000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 362999000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 50129000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 50129000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Minority Interests: -367000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income: 4812000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 4812000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 5179000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 4812000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 4812000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 5179000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -50129000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -50129000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 82646000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 4812000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Operating Income: 50728000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 731544000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 5065000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 125666000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 5663000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 368545000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 26854000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Special Income Charges: 0.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 484000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.09
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 680816000.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items: 0.00
BALPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — +Operating Expense: 1254009000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 324431000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — +Total Revenue: 3030833000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 818762000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 816858000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 816858000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 924435000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 924435000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -520371000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 319779000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -15422000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -15422000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Amortization: 35929000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 42347000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 42347000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 15823026.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 15979706.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Basic EPS: 4.56
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 3.40
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 41958000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 293931000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -187868000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 19272000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 159209000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 159209000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 17516000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 17516000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 104102000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 104102000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -19105000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 9416000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -152109000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -38093000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: -6123000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Payable: 41666000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Receivables: 71844000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -74893000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Changes In Cash: -24443000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock: 159209000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 159209000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 774159000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 774159000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 1412000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 43756000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 43756000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 1578934000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 439730000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Assets: 2348720000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 2348720000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt: 1189998000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 1189998000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 1189998000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 1189998000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 2195003000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 2195003000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 11671000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 11671000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation: 97709000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 97709000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 97709000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 21803000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 97709000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 21803000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 15823026.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 15979706.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Diluted EPS: 4.56
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 3.40
BALPHARMA.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 72153000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 54331000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 1079000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — EBIT: 219919000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — EBIT: 65430000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — EBITDA: 317628000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — EBITDA: 87233000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: 0.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — End Cash Position: 17516000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -78424000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 308360000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 15282000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: 0.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 46196000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Goodwill: 38269000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 38269000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 158244000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 158244000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 939858000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 737763000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 1274036000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Gross Profit: 1451899000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 379032000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense: 168544000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 39496000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 168544000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 39496000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -168544000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 7364000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Inventory: 1030222000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 1030222000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 2277961000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 2278291000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -149169000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 42347000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 71304000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 1412000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 0.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 172713000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 12897000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 314134000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 314134000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 314134000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 314134000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 0.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -7674000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 56446000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 56446000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 763636000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Minority Interest: -115000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: -115000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Minority Interests: -213000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 146000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: 0.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 1412000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Net Debt: 1486286000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 1486616000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 2068000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Net Income: 72154000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income: 54332000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 72154000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 54332000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 72367000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 54185000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 72153000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 54331000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 72154000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 54332000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 51374000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 72367000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 54185000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Net Interest Income: -168544000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -39496000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 31325000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 107812000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -7674000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -168544000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -39496000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Net Other Financing Charges: 1000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Net PPE: 753665000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 753665000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -187868000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 115486000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 615915000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 615915000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 4098000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 4098000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 0.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 0.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 56446000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 317628000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 87233000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Normalized Income: 72153000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 54331000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 203150000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Operating Income: 197890000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Income: 54601000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Operating Revenue: 3030833000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 818762000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 15920872.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 15920872.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Other Cash Adjustment Outside Changein Cash: 1000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 254893000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 254893000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 69266000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 69266000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 614950000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 614950000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 119975000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 119975000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 59654000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 59654000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: 147661000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 1708000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 36774000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: -2000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 22029000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 10830000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 532295000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 147721000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 32515000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Properties: 709905000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 709905000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 42491000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 11328000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 86586000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 100442000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Other Special Charges: -135000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Payables: 850452000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Payables: 850452000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 220518000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Pretax Income: 51375000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 25934000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 0.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of Business: 0.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -187868000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 327135000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 1578934000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 439730000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 97709000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 21803000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 10080000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 10080000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -7674000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 11412000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 11412000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 273104000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 273104000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 0.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 193930000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 240126000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Share Issued: 15920872.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 15920872.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Special Income Charges: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Stock Based Compensation: 0.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 774159000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 774159000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 615915000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 615915000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Tax Provision: -20992000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Provision: -28251000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.30
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.30
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 9884000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 9884000.00
BALPHARMA.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -20771000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Assets: 3356902000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 3356903000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 1088293000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 1088293000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Debt: 1504132000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 1523074000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 774044000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 774044000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Total Expenses: 2832943000.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 764161000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 2582859000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 2582858000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 1008183000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 1008183000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 387856000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 387856000.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 25162000.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 0.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 0.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
BALPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
BALPHARMA.NS balance_sheet (annual, 2025-03-31) — Working Capital: 153717000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 153717000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 287886000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 658709000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 15430769.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 0.13
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 335426000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 25204000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 25204000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 15430769.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.13
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 2006000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — EBIT: 42619000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — EBITDA: 67823000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 323283000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 40534000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 40534000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Minority Interests: -79000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income: 2006000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 2006000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 2085000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 2006000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 2006000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 2085000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -40534000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -40534000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 67823000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 2006000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Income: 35397000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 658709000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 7222000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 114645000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 2085000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 335426000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 25204000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 623312000.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 306302000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 740249000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 842035000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 908235000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 48184000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 15766667.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 0.45
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 159209000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 15807000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 106559000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 159209000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 783261000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 30083000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 399353000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 2450095000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 1235123000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 1235123000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 2288966000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 11640000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 22710000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 22710000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 15766667.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 0.45
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 7095000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — EBIT: 45753000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — EBITDA: 68463000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Goodwill: 38269000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 162924000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 792056000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 340896000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 38580000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 38580000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 1126916000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 2332052000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 48184000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 313668000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 313668000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 52815000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Minority Interest: 43000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Minority Interests: -77000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Net Debt: 1532984000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income: 7095000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 7095000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 7173000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 7095000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 7095000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 7173000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -38580000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -38580000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 792056000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 620337000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 4098000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 68463000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 7095000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Operating Income: 34594000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 740249000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 15920872.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 296158000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 62422000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 624052000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 124655000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 36348000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: -1000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 11159000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 120878000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 761973000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Receivables: 11909000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 90752000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Payables: 842035000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 318000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 7173000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 399353000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 22710000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 15920872.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 783261000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 620337000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 3493705000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 1096929000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 1548791000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 783304000.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 705655000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 2710401000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 1043610000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 421435000.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
BALPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 161129000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 352146000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 876897000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 15891964.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 1.12
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 461599000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 32299000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 32299000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 15891964.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 1.12
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 17799000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — EBIT: 66409000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — EBITDA: 98708000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 415298000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 48503000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 48503000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Minority Interests: -107000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income: 17799000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 17799000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 17906000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 17799000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 17799000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 17906000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -48503000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -48503000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 98708000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 17799000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Income: 63152000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 876897000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 3262000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 146606000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 17906000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 461599000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 32299000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 813745000.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: 0.00
BALPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 0.00
BALPHARMA.NS income_statement (annual, 2026-03-31) — +Operating Expense: 1328725000.00
BALPHARMA.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 382391000.00
BALPHARMA.NS income_statement (annual, 2026-03-31) — +Total Revenue: 3116613000.00
BALPHARMA.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 840757000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 889684000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 889684000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 936327000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 936327000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 80709000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 80709000.00
BALPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 15900442.00
BALPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 2.26
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 17516000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -223800000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 159209000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 159209000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 23011000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 23011000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 109318000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 109318000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -19105000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -133332000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -138409000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 200638000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Payable: 68899000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -19747000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -20318000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 1571000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock: 159209000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 159209000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 822274000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 822274000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 0.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Common Stock Payments: -1000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 74242000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 74242000.00
BALPHARMA.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 1579651000.00
BALPHARMA.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 383272000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Assets: 2622336000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 2622336000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt: 1276316000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 1276316000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 1276316000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 1276316000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 2492280000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 2492280000.00
BALPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 7763000.00
BALPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 7763000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation: 110793000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 110793000.00
BALPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 110793000.00
BALPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 30580000.00
BALPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 110793000.00
BALPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 30580000.00
BALPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 15900442.00
BALPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 2.26
BALPHARMA.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 62836000.00
BALPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 35935000.00
BALPHARMA.NS income_statement (annual, 2026-03-31) — EBIT: 227514000.00
BALPHARMA.NS income_statement (quarterly, 2026-03-31) — EBIT: 72729000.00
BALPHARMA.NS income_statement (annual, 2026-03-31) — EBITDA: 338307000.00
BALPHARMA.NS income_statement (quarterly, 2026-03-31) — EBITDA: 103309000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: 0.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — End Cash Position: 19086000.00
BALPHARMA.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -95864000.00